INCY - Incyte Corporation
64.44 0.00 (0.00%)
After hours: 5:00PM EDT
| Previous Close | 65.04 |
| Open | 65.35 |
| Bid | 62.81 x 900 |
| Ask | 66.09 x 1400 |
| Day's Range | 63.49 - 65.49 |
| 52 Week Range | 60.23 - 117.95 |
| Volume | 901,318 |
| Avg. Volume | 1,437,469 |
| Market Cap | 13.698B |
| Beta (3Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.49 |
| Earnings Date | Oct 30, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.60 |
- GlobeNewswire•6 days ago
Report: Developing Opportunities within Packaging Corporation of America, Jones Energy, Pitney Bowes, Mercury General, Invacare, and Incyte — Future Expectations, Projections Moving into 2018
NEW YORK, Oct. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•7 days ago
Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales
Incyte's (INCY) performance is likely to be strong due to rising demand of lead drug, Jakafi.
- Business Wire•8 days ago
Incyte to Report Third Quarter Financial Results
Incyte Corporation announced today that it has scheduled its third quarter 2018 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 30, 2018.
- Business Wire•10 days ago
Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress
Interim Phase 2 results highlight the potential of pemigatinib in cholangiocarcinoma and urothelial carcinoma
- Motley Fool•10 days ago
3 Top Biotech Stocks to Buy in October
Adding these biotech stocks to growth portfolios this month could prove to be profit-friendly.
- Motley Fool•10 days ago
Are These Beaten-Down Clinical-Stage Biotech Stocks Buys?
A partner walks away and trial data fails to impress. Here's what's next for these biotech upstarts.
- TheStreet.com•14 days ago
Tesla, Facebook, Amazon and Netflix Lead the Nasdaq's Sharp Decline
The major U.S. equities were tanking Thursday, Oct. 4, after a bond selloff sent 10-year benchmark U.S. Treasury yields rising more than 3%. The Nasdaq dropped 2.05% to 7,861, while the Dow Jones Industrial Average and S&P 500 both fell less than 1% on the day.
- Market Realist•15 days ago
Ionis Pharmaceuticals’ Valuations on September 28
Ionis Pharmaceuticals (IONS) develops drugs for life-threatening diseases, and it commercializes the approved products in collaboration with other pharmaceutical companies. Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in YoY (year-over-year) revenues compared to the second quarter of 2017.
- Motley Fool•21 days ago
Better Buy: Geron Corporation vs. Incyte Corporation
The decision might not be as easy as it seems at first glance.
- Investor's Business Daily•22 days ago
Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance
In stock news today, strong showings from biotech stocks Alexion and Incyte lifted the Nasdaq 100 to a gain of nearly 1% in afternoon trading.
Market Realist•23 days agoJ&J Files for US Approval of Cancer Drug Erdafitinib
On September 18, Johnson & Johnson (JNJ) announced that it had submitted a new drug application to the FDA for its investigational drug, erdafitinib, for the treatment of locally advanced or metastatic UC (urothelial cancer) in patients with certain FGFR (fibroblast growth factor receptor) genetic alterations. The application is based on the findings of BLC2001, a Phase 2 study. Erdafitinib, one of the company’s key pipeline products, is expected to drive growth. The diagram below shows some of J&J’s recent pharmaceutical launches and filings expected over the next few years. In March, J&J received breakthrough therapy designation for erdafitinib from the FDA.
- Market Realist•27 days ago
A Look at Sage Therapeutics’ NMDA Receptor Portfolio
As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.
- Market Realist•28 days ago
Shire’s Quarterly Revenue Trend
Biotechnology company Shire (SHPG) reported a 4.6% YoY (year-over-year) rise in revenue to ~$3.9 billion in the second quarter compared to $3.7 billion in the second quarter of 2017.
- Simply Wall St.•28 days ago
Is Incyte Corporation (NASDAQ:INCY) As Strong As Its Balance Sheet Indicates?
Incyte Corporation (NASDAQ:INCY), a large-cap worth US$14.42b, comes to mind for investors seeking a strong and reliable stock investment. Most investors favour these big stocks due to their strong balanceRead More...
- Zacks•last month
Agenus Receives Milestone Payment of $5 Million from Incyte
Agenus (AGEN) receives a milestone payment of $5 million from Incyte on the initiation of a phase I study of INCAGN2385.
Markit•last monthSee what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCY
- Business Wire•last month
In Honor of MPN Awareness Day and Blood Cancer Awareness Month, Incyte Debuts Documentary Spotlighting Myeloproliferative Neoplasms (MPNs)
WILMINGTON, Del.-- -- Directed by an Academy Award ® winning filmmaker in the documentary short subject category, “Something So Rare” chronicles the lives of four people living with MPNs, rare blood cancers MPN community encouraged to access new resources and participate in awareness initiatives in support of MPN Awareness Day Today on MPN Awareness Day and throughout September, Blood Cancer Awareness ...
- Business Wire•last month
Incyte Announces Positive Data from Phase 2b Trial of Ruxolitinib Cream in Patients with Atopic Dermatitis
WILMINGTON, Del.-- -- Study met primary and key secondary endpoints, demonstrating significant improvement from baseline in EASI score and reduced itch compared to vehicle Results presented at EADV support planned initiation of global, pivotal Phase 3 program Incyte Corporation today announced positive results from its randomized, dose-ranging, vehicle- and active-controlled Phase 2b study evaluating ...
- Zacks•last month
Biotech Stock Roundup: GILD's Arthritis Drug Successful in Phase III, PRQR Soars
Pipeline updates and collaborating agreement comprise some of the key developments in the biotech sector this week.
- Zacks•last month
Incyte, Foundation Medicine Partner for Companion Diagnostics
Incyte (INCY) inks an agreement with Foundation Medicine for the development of companion diagnostics (CDx) for Incy's selective FGFR Inhibitor, pemigatinib.
- Benzinga•last month
The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...
- Business Wire•last month
Incyte and Foundation Medicine Announce Agreement to Develop Companion Diagnostic for Pemigatinib (INCB54828), a Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
Incyte Corporation (INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx development for pemigatinib (INCB54828), Incyte’s selective FGFR1/2/3 inhibitor, in patients with cholangiocarcinoma. The initial CDx, which will include detection of activating FGFR2 translocations, is expected to be incorporated into FoundationOne®CDx, Foundation Medicine’s FDA-approved comprehensive genomic profiling (CGP) assay and broad CDx platform. “There is an urgent need for a novel, biomarker-based, targeted therapeutic approach for patients with cholangiocarcinoma.
- Benzinga•last month
The Week Ahead In Biotech: Conferences, Clinical Trial Results, Earnings And IPOs
After recording stellar gains of 4.3 percent in the week ended Aug. 31 to close the month in the green, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) saw a moderation in momentum in the holiday-shortened ...
- Benzinga•last month
5 Stocks To Have On Your Radar Next Week
The following stocks are currently in the midst of strong trendsaccording to VantagePoint , an AI charting platform that uses intermarket analysis and artificial intelligence to predict future price action ...
